SCHEMBL23826331

SCHEMBL23826331

COC(=O)c1cc(F)c(OC(F)F)c(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.43
POLB P06746 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
KDM4E B2RXH2 3/20 0.42
LMNA P02545 1/20 0.42
GAA P10253 1/20 0.42
NFKB1 P19838 1/20 0.42
XDH P47989 1/20 0.42
GFER P55789 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
FUT7 Q11130 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
TPMT P51580 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30628771 1.00 NOTUM (0.43) NOTUMPOLBL3MBTL1KDM4ELMNA
SCHEMBL1561433 0.84 TPMT (0.51) NOTUMPOLBL3MBTL1KDM4ELMNA
SCHEMBL29759239 0.84 TPMT (0.51) NOTUMPOLBL3MBTL1KDM4ELMNA
SCHEMBL26632380 0.78 MAPK1 (0.38) NOTUML3MBTL1KDM4ELMNAGAA
SCHEMBL30628765 0.78 POLB (0.36) NOTUMPOLBL3MBTL1KDM4ELMNA
SCHEMBL26632410 0.78 POLB (0.36) NOTUMPOLBL3MBTL1KDM4ELMNA
SCHEMBL403251 0.78 NOTUM (0.42) NOTUMPOLBL3MBTL1KDM4ELMNA
SCHEMBL1726759 0.77 KDM4E (0.50) NOTUMPOLBL3MBTL1KDM4ELMNA
SCHEMBL30164563 0.77 KDM4E (0.50) NOTUMPOLBL3MBTL1KDM4ELMNA
SCHEMBL400542 0.76 POLB (0.58) NOTUMPOLBL3MBTL1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4516778-A1 COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2025-03-05 EP disclosed
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2022-01-27 US disclosed
EP-3882239-A1 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2021-09-22 EP disclosed
CN-113302184-A 1,3, 4-oxadiazolinone compounds and drugs 日本新药株式会社 2021-08-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL PIM1, PIM3, PIM2 NOTUM 1103/4885POLB 3559/4885L3MBTL1 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.